All Press Releases for October 15, 2024

Marquis Who's Who Honors Pannie Trifillis, PhD, for Expertise in Health Care

Pannie Trifillis, PhD, is an expert consulting clinical-stage biotech companies on optimizing commercialization of therapies for patients living with rare diseases



She has contributed to scientific and medical advancements through numerous articles published in peer-reviewed professional journals including the top-tier journals of Nature and Science.

    WHITEHOUSE STATION, NJ, October 15, 2024 /24-7PressRelease/ -- Pannie Trifillis, PhD, has been selected for inclusion in Marquis Who's Who. As in all Marquis Who's Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all considered during the selection process.

Dr. Trifillis is an accomplished executive with 25 years of experience in the biopharmaceutical industry. As the Senior Vice President of Medical Affairs and Scientific Communications at Rapid Commercialization Partners (RCP), she consults biotech companies on how to best launch drugs for rare diseases, allowing those companies to better educate physicians and reach patients that desperately need these drugs. RCP is based in Cambridge, Massachusetts. The consulting company offers a suite of services focused on optimizing commercialization of drugs for clinical-stage biotechnology companies in preparation for future commercial success. In addition to her work there, Dr. Trifillis is a founding partner at Precision Science Consulting LLC as of 2023. Based in New Jersey, her firm provides consulting services in drug development specifically in scientific affairs, strategic planning, alliance management and medical affairs.

In preparation for her career in the sciences and recognizing her hard work in academics, Dr. Trifillis received a Fulbright Visiting Scholar award from Cyprus through the Fulbright Program by the U.S. Department of State Bureau of Educational and Cultural Affairs. The Fulbright scholarship enabled Dr. Trifillis to receive a Bachelor of Arts in biology and chemistry with a minor in sociology from Wellesley College in 1988 and subsequently, a Doctor of Philosophy in molecular biology and human genetics from the University of Pennsylvania in 1994. She also earned several certifications including those from the Association of Strategic Alliance Professionals, the Kellogg School of Management at Northwestern University and other professional organizations.

Dr. Trifillis's career began as a postdoctoral fellow at the Cyprus Institute of Neurology and Genetics from 1994 to 1996, followed by a similar role at Rutgers University, NJ between 1996 and 1999. She then joined PTC Therapeutics, Inc., as the first employee and scientist holding various positions from research to alliance management, to medical affairs for 25 years. By 2017, Dr. Trifillis had worked up to Executive Director of Global Medical Affairs (GMA) and Head of Global Scientific Affairs (GSA) before being promoted to Vice President of GMA and Head of GSA in 2018. During her tenure at PTC, she was instrumental in the commercial launch of five rare disease drugs around the world.

Throughout her career, Dr. Trifillis has been passionate about discovering, developing and commercializing drugs for patients living with rare genetic diseases. She is particularly proud of the discovery and development of Translarna (ataluren) and Evrysdi (risdiplam), which, respectively, became available for patients with Duchenne Muscular Dystrophy in 2014 and for those with Spinal Muscular Atrophy in 2020. Dr. Trifillis's scientific innovation and rigor earned her a U.S. patent in "Methods for identifying compounds that modulate untranslated region-based regulation and methods of using the same". Dr. Trifillis has also greatly contributed to scientific and medical advancements in her field through numerous articles published in peer-reviewed professional journals including the top-tier journals of Nature and Science.

Active in her professional community, Dr. Trifillis holds membership in the American Association for the Advancement of Science, the American Society of Gene and Cell Therapy, the Hellenic Medical Society of New York, the World Muscle Society, and the Association of Strategic Alliance Professionals. In 2023, she was also recognized as an honorary member of the Cyprus Biological Society at the University of Cyprus Medical School.

In addition to her professional achievements, Dr. Trifillis is actively involved in several volunteer non-profit organizations. She serves on the Cyprus Children's Fund Inc. Board of Directors, is the Vice President and Secretary on the Board of Directors for the Association of Greek American Professional Women and is a mentor and an Advisory Committee Member for ALLILONnet. Previously, Dr. Trifillis was active on the Board of Directors for the Political Action Committee at PTC Therapeutics, Inc.

In the media, Dr. Trifillis was featured on the cover of The National Herald's monthly magazine "The Woman" in an article entitled "Pannie Trifillis: Female Scientist of the Greek American Community" in May of 2019. She was also a guest on the "Cypriots of the World" television program of the Cyprus Broadcast Corporation in October of 2020 where she was interviewed about her life and career. In April of 2024, Dr. Trifillis, as a dual Cypriot American citizen, was also featured in the cover story of the GOLD business magazine, entitled "Living the American Dream: How 9 Cypriot expatriates achieved success in the USA".

Eager for the future, Dr. Trifillis aims to continue her work helping patients with rare diseases access treatments that they so desperately need. She also remains dedicated to advancing applied science to benefit patients and their families. Dr. Trifillis draws constant inspiration and support from her husband Dr. Mike Kiledjian, who chairs the Department of Cell Biology and Neuroscience at Rutgers University in New Jersey, and their two adult children.

About Marquis Who's Who®:
Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America®, Marquis Who's Who® has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Who's Who in America® remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. The suite of Marquis® publications can be viewed at the official Marquis Who's Who® website, www.marquiswhoswho.com.

# # #

Contact Information

-- --
Marquis Who's Who Ventures LLC
Uniondale, NY
USA
Voice: 844-394-6946
E-Mail: Email Us Here
Website: Visit Our Website
Follow Us: